Reading this collection
This cluster carries a wider range of evidence tiers than most — from a national-academies summary through systematic review to mechanistic work on sleep architecture. Read the tier label before the finding.
Sleep endpoints are also notoriously sensitive to how they were measured: self-reported sleep quality and polysomnographic architecture are different outcomes and do not substitute for one another.
The evidence in this library
7 source-linked studies — 4 scientific source · 2 guideline / official boundary · 1 peer-reviewed review. Each links to its source; identifiers are shown where the record carries them.
-
Cannabidiol and Sleep Disorders — GABA-A Potentiation, REM Architecture
Scientific source
PMID 29381457
-
Summary — The Health Effects of Cannabis and Cannabinoids
Guideline / official boundary
-
Cannabinoids and Sleep: Systematic Review of Current Evidence
Guideline / official boundary
PMID 25271780
-
CBD and Cannabinoids for Sleep Disorders: Large Clinical Case Series
Scientific source
PMID 32350861
-
Linalool (Lavender / Sleep Sutra): GABA-A Anxiolytic and Sleep Onset Terpene
Scientific source
PMID 12587690
-
Nardostachys jatamansi: Phytochemistry, Ethnomedicine and Pharmacology
Peer-reviewed review
PMID 38042505
-
HPA-axis modulation with botanical interventions (Ashwagandha)
Scientific source
PMID 33650944
How to read this evidence
These are the boundaries recorded against the studies above, reproduced as written in the library:
- Supportive symptom research; avoid guaranteed anxiolytic, sedative, or psychiatric treatment claims.
- Sleep symptom support; condition-specific and short-term.
- Research-navigation wording only; clinical use requires physician judgment and local regulatory compliance.
- Use as evidence-informed ECS/cannabinoid research navigation; avoid product-specific disease claims.